Borralleras C, de Cambra S, Barreiro A, Prenafeta A, Madrenas L, Cañete M, et al. 

There is still a need for broad-spectrum vaccines that may cross protect from new genetic variants of SARS-CoV-2 and provide a long-lasting immune response. PHH-1V (BIMERVAX®, HIPRA) is a bivalent recombinant protein vaccine based on a heterodimer consisting of the receptor binding domain of two SARS-CoV-2 variants, Beta and Alpha, designed to boost immunogenicity against SARS-CoV-2 in fully vaccinated adult individuals.